Jazz Pharmaceuticals PE ratio JAZZ

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Oct 23, 2026: 14.6×
10-year median: 20.2×
Against its 10-year history: 15th; percentile: 0 is its lowest day, 100 its highest
10-year range: 10.6× to 158×
Peer median: 61.7×

Jazz Pharmaceuticals' PE ratio is 14.6× as of Oct 23, 2026: a share price of $214.00 against $14.62 of earnings per share over the last twelve months.

That is below its ten-year median of 20.2×, lower than on 85% of days in the last ten years.

Over that time it ranged from 10.6× in Mar 2020 to 158× in Aug 2021.

The median for 10 large drugmakers of a similar size is 61.7×.

PE ratio over time

median 20.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	14.6×	14.4×	17.5×
2025	15.4×	11.4×	19.3×
2024	17.7×	17.3×	150×
2023	140×	135×	140×
2022	n/m a value too high to mean anything
2021	142×	18.6×	158×
2020	52.1×	10.6×	67.3×
2019	14.4×	10.7×	19.8×
2018	14.4×	13.7×	25.7×
2017	22.2×	20.1×	24.8×
2016	19.1×	17.9×	30.0×
2015	27.0×	25.8×	408×
2014	387×	21.4×	415×
2013	20.9×	11.5×	25.4×
2012	23.2×	15.8×	24.3×

Against its peers

Companies in Drug Manufacturers - General nearest Jazz Pharmaceuticals' size, closest first, today.

Company	PE ratio
JAZZJazz Pharmaceuticals	14.6×
BMRNBiomarin Pharmaceutical	151×
CORTCorcept Therapeutics	204×
PTGXProtagonist Therapeutics	134×
TGTXTG Therapeutics	19.8×
ALKSAlkermes plc.	115×
AMRXAmneal Pharmaceuticals	41.6×
LGNDLigand Pharmaceuticals	32.3×
KNSAKiniksa Pharmaceuticals International	79.1×
BIIBBiogen	44.4×
INDVIndivior Pharmaceuticals	12.4×
Peer median	61.7×

Where Jazz Pharmaceuticals ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Jazz Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.